Loading…
← CockpitCompetitor Analysis › 4534.T Mochida Pharmaceutical Co., Ltd.Open in the cockpit ↗

Mochida Pharmaceutical Co., Ltd.4534.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum strong 62
Mkt cap
$714M
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$924,843
20-day average traded
Fwd P/E
16.1×
forward earnings
ROIC−WACC
+1.9 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
82 days
8 Feb 2027
Close · JPY¥3,325
1D-1.3%
1W+1.2%
1M+3.1%
3M+2.3%
6M-2.6%
YTD-5.9%
1Y+9.2%
ATR %2.2%
52w lowhigh16.1% off high

What Mochida Pharmaceutical does

Employees: 1,479

Mochida Pharmaceutical at a glance

Size Mochida Pharmaceutical (4534.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $714M, the 899th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,325 on 18 Nov 2026.

Performance Over six months the shares fell 2.6%, against -15.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 15.8% over the last twelve months (peer median +3.2%); the operating margin is 9.7% (peer median 9.6%).

Valuation It trades at 16.1× forward earnings against a peer median of 15.2× (6th cheapest of 11).

Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 20264534.T 95Peer median 86
Six months, rebased to 100: Mochida Pharmaceutical against the median of its 20 peers (local-currency closes).

Mochida Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥126B¥117B¥105B¥103B¥103B
Revenue growth—+11%+2%0%—
Gross profit¥59.5B¥56.3B¥53.8B¥52.1B¥55.1B
EBITDA¥15.7B¥13.1B¥11.1B¥8.61B¥11.2B
Net income¥10.8B¥7.90B¥5.68B¥4.55B¥6.65B
Free cash flown/a-¥10.0B¥7.19B-¥9.78B¥5.13B
Capital expendituren/a¥2.69B¥2.16B¥2.30B¥2.17B
Total debt¥10.0B¥10.3B¥342M¥369M¥190M

Quarterly statements and history in the cockpit →

Mochida Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%-10%0%0570603998SGMT688799600530688566600829NVCT218630070549850009156004792171002907600351002424688658PHIL6884884534.T6-month return →1-month return →
Up and to the right = strong over both horizons. Mochida Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×60399868879968856621864985000915688658PHIL6884884534.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mochida Pharmaceutical is the large dot.

Mochida Pharmaceutical competitors and peer comparison

How Mochida Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mochida Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4534.TPeer medianRank in peer set
1-month return+3.1%-8.4%3rd highest of 21
6-month return-2.6%-15.3%7th highest of 21
Distance from 52-week high-16.1%-36.1%4th highest of 21
Revenue growth (TTM)+15.8%+3.2%3rd highest of 19
Operating margin9.7%9.6%9th highest of 19
Forward P/E16.1×15.2×6th cheapest of 11
ROIC minus cost of capital+1.9 pp+0.7 pp8th highest of 17
EV / EBITDA6.1×3.6×2nd most expensive of 5
Net debt / EBITDA-1.2×-1.4×2nd most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%

Questions

Which companies are Mochida Pharmaceutical's closest peers?
The cockpit's peer set: China Traditional Chinese Medicine (0570.HK), Hunan Fangsheng Pharmaceutical (603998.SS), Sagimet Biosciences (SGMT), Hunan Warrant Pharmaceutical (688799.SS), Shanghai Jiaoda Onlly (600530.SS), Jiangsu Jibeier Pharmaceutical (688566.SS), HPGC Renmintongtai Pharmaceutical (600829.SS), Nuvectis Pharma (NVCT).
Is Mochida Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.1× against a peer median of 15.2×, 6th cheapest of 11 in its peer set.
How has Mochida Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -2.6% against -15.3% for the median peer; over one year +9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.